The Global Allogeneic Cell Therapy Manufacturing Market is valued at US$ 869.6 Mn in 2021, and it is expected to reach US$ 3424.1 Mn by 2030, with a CAGR of 17 % during a forecast period of 2022-2030. Allogeneic cell therapies involve the transfer of cells from a donor to a patient. Allogeneic cells are collected from various sources, among which blood is the prominent source for allogeneic cells. The small volume of blood comprises many cells that quickly gets multiply.
The key factors driving the growth of the allogeneic cell therapy manufacturing market include the rising elderly population, high prevalence of chronic diseases, the growing demand for personalized treatments, increasing healthcare expenditure, rapid technological advancements in the healthcare sector. Many biopharma companies are collaborating to improve research and development activities in stem cell research, considering the need for allogeneic cell therapies. Likely to propel the growth opportunities for the allogeneic cell therapy manufacturing market in the forthcoming years. For instance, in September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group member, Genentech, to develop and market allogeneic cell therapies to treat multiple cancer indications.
However, the expensive manufacturing of allogeneic cell therapies and the risks associated with allogeneic cell therapies may hamper the market growth over the forecast period.
The allogeneic cell therapy manufacturing market is classified based on products, scale of operation, and region. By products, the market Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product. The mesenchymal stem cells (MSCS) segment is expected to hold the maximum market share in the coming days due to the increasing R&D activities in stem cell therapies. The market is classified Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations in terms of scale of operation.
Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to hold the maximum share of the market over the forecast years, followed by Europe owing to the growing patients of chronic diseases and surging R&D activities by key players to develop effective allogeneic cell therapies.
Some of the key players operating in the allogeneic cell therapy manufacturing market are Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and others.
